Bureau Veritas appoints Santiago Arias Duval as Executive Vice-President for the Americas region
17.11.2025 08:00:00 CET | Business Wire | Press Release
Bureau Veritas, a global leader in Testing, Inspection and Certification (TIC), is pleased to announce the appointment of Santiago Arias Duval, effective November 17th, 2025, as Executive Vice-President, Americas. This appointment is in line with Bureau Veritas’ new operating model effective since September 1st, 2025.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251116192035/en/
Hinda Gharbi, CEO at Bureau Veritas
Bureau Veritas is evolving the structure of its executive committee to drive greater organizational alignment. This organization will empower the regions with scalable Product Lines, enabling global solutions development, and will be unlocking wider cross-selling opportunities.
The Americas region is created to leverage fast developing market opportunities across countries in North, Central and South America. This is a dynamic region for all Bureau Veritas where the group intends to expand its leadership across product lines and create new strongholds in high growth markets. The new Americas region organization will facilitate the scaling of new solutions and services and will enable superior resources utilization across all Product Lines.
Santiago Arias Duval will report to Hinda Gharbi, Chief Executive Officer of Bureau Veritas, and joins the Group Executive Committee.
Hinda Gharbi, Chief Executive Officer of Bureau Veritas, commented: “I am delighted to welcome Santiago to the Group Executive Committee. With his wide industrial experience, proven business achievements and global operations exposures, he will drive our growth and development agenda in North, Central and South America. I am confident that Santiago and the Americas teams will take the region to the next level of growth and performance and will deliver on our LEAP I 28 ambition.
Santiago Arias Duval, Executive Vice-President, Americas commented: "I am honored to join Bureau Veritas and its talented teams across North, Central and South America. The region presents a significant opportunity for growth and for building on the company's strong foundation of technical excellence, innovation, and trust. I look forward to working closely with Hinda, the Executive Committee, and the Americas team to accelerate growth, deepen our customer relationships, and advance the ambitions of the Leap I 28 strategy."
***
Biography:
Santiago Arias Duval served as Senior Vice President and General Manager of Precision Technologies at Ingersoll Rand. In this role, he was responsible for the overall strategy, operations, and commercial performance of a diverse set of businesses serving customers across multiple industries worldwide.
Joining Ingersoll Rand in 2017, Santiago held a series of leadership roles of increasing responsibility, including General Manager of Industrial Pumps and Medical North America and Vice President and General Manager of the Vacuum & Liquid Handling, and Life Sciences businesses. Throughout his tenure, Santiago has consistently delivered above-market organic growth, executed multiple acquisitions, and driven significant EBITDA margin expansion through commercial excellence, operational efficiency, and disciplined portfolio management.
Before joining Ingersoll Rand, Santiago held leadership positions at Danaher Corporation, where he served as Packaging Business Unit Leader for X-Rite and as a consultant within the Danaher Business System Office, supporting global operating companies on new product commercialization. Earlier in his career, he worked in product management at Fluke (Danaher) and in operations at General Motors.
Santiago holds a Master of Business Administration from the Massachusetts Institute of Technology (MIT) and a Bachelor of Science in Electrical Engineering from the Georgia Institute of Technology.
***
About Bureau Veritas
Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress. With a vision to be the preferred partner for customers’ excellence and sustainability, the company innovates to help them navigate change.
Created in 1828, Bureau Veritas’ 84,000 employees deliver services in 140 countries. The company’s technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability.
Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40, CAC 40 ESG, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI.
For more information, visit http://www.bureauveritas.com, and follow us on LinkedIn.
Our information is certified with blockchain technology.
Check that this press release is genuine at www.wiztrust.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251116192035/en/
Contacts
ANALYST/INVESTOR CONTACTS
Laurent Brunelle
+33 (0) 7 79 52 69 21
laurent.brunelle@bureauveritas.com
Colin Verbrugghe
+33 (0) 6 80 53 26 72
colin.verbrugghe@bureauveritas.com
Romain Gorge
romain.gorge@bureauveritas.com
Inès Lagoutte
ines.lagoutte@bureauveritas.com
MEDIA CONTACTS
Martin Bovo
+33 (0)6 14 46 79 94
martin.bovo@bureauveritas.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom